Measuring Acute Drug Demand in Humans

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT05829655
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Opioid Dependence
  • Opioid Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Drug A (Blinded Drug) — DRUG
    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
  • Drug B (Blinded Drug) — DRUG
    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
  • Drug C (Blinded Drug) — DRUG
    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
  • Drug D (Blinded Drug) — DRUG
    Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
  • Suvorexant (20mg/day) — DRUG
    Double blind administration of suvorexant once per day during residential stay until discharge.
  • Placebo — DRUG
    Double blind administration of placebo once per day during residential stay until discharge.

Study Details

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Key Dates

Start date
Aug 8, 2023
Status verified
Jun 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Suvorexant (20mg/day)
    Double blind administration of suvorexant once per day during residential stay until discharge
  • Placebo Comparator: Placebo
    Double blind administration of placebo once per day during residential stay until discharge

Primary Outcome Measure

Demand Intensity [ Time Frame: Upon completion of experimental session (~8 hours post drug administration) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
General Clinical Research CenterBaltimoreMaryland21201
Justin Strickland, PhD
[email protected]
667-354-3516
Justin Strickland, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
General Clinical Research Center· Baltimore, MD

Related Studies